Catabasis craters after giving up on muscular dystrophy leadCatabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after Share XCatabasis craters after giving up on muscular dystrophy leadhttps://pharmaphorum.com/news/catabasis-craters-after-giving-up-on-muscular-dystrophy-lead/
EMA starts rapid review of Bluebird’s gene therapy for rare disease CALDBluebird bio could be just a few months away from approval of its gene therapy for rare disease Share XEMA starts rapid review of Bluebird’s gene therapy for rare disease CALDhttps://pharmaphorum.com/news/ema-starts-rapid-review-of-bluebirds-gene-therapy-for-rare-disease-cald/
Life with multiple myelomaMultiple myeloma patient Bob Munro (pictured below) explains what it’s like to live with the rare blood cancer and Share XLife with multiple myelomahttps://pharmaphorum.com/partner-content/life-with-multiple-myeloma/
